Loading…

Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76

Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes. We examined the relati...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2006-12, Vol.49 (12), p.2892-2899
Main Authors: CALLE, R, MCCARTHY, M. I, MANCUSO, J, MILOS, P, FRYBURG, D, HOLMAN, R. R, BANERJEE, P, ZEGGINI, E, CULL, C. A, THORNE, K. I, WILTSHIRE, S, TERRA, S, MEYER, D, RICHMOND, J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3
cites cdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3
container_end_page 2899
container_issue 12
container_start_page 2892
container_title Diabetologia
container_volume 49
creator CALLE, R
MCCARTHY, M. I
MANCUSO, J
MILOS, P
FRYBURG, D
HOLMAN, R. R
BANERJEE, P
ZEGGINI, E
CULL, C. A
THORNE, K. I
WILTSHIRE, S
TERRA, S
MEYER, D
RICHMOND, J
description Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes. We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors. rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus. We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes.
doi_str_mv 10.1007/s00125-006-0436-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68139521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68139521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxUOxtGv1D_BFgmCxD1NvMpl89E3a2orFLmjBt5DJB06ZScZkpnT_e2fZhYJPl8v5nQP3HoTeETgnAOJzASC0qQB4BazmlTxAK8JqumxUvkKrrVwRyX8fo9elPAJA3TB-hI6JAMUJkSvk1yab9JyiKR5T_Gl9_4Oe4TH1myHl8U9XhoJNdNj5J9-ncfBxwing7KPpsduUMEc7dSniLuJpM24zXGdaP_mCL_DD9_XVTyz4G3QYTF_82_08QQ9fr39d3lZ39zffLr_cVbZWaqqkAhcaDuCElOCtIybUAogH2xBHhGqFCtDY0FJuFGHApWRgfGBOGQptfYJOd7ljTn9nXyY9dMX6vjfRp7loLkmtGkoW8MN_4GOa83JT0YsqmWCcLRDZQTanUrIPeszdYPJGE9DbAvSuAL0UoLcFaLl43u-D53bw7sWx__gCfNwDpljTh2yi7coLJ6lSgrL6H0u2i0c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213847464</pqid></control><display><type>article</type><title>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</title><source>Springer Link</source><creator>CALLE, R ; MCCARTHY, M. I ; MANCUSO, J ; MILOS, P ; FRYBURG, D ; HOLMAN, R. R ; BANERJEE, P ; ZEGGINI, E ; CULL, C. A ; THORNE, K. I ; WILTSHIRE, S ; TERRA, S ; MEYER, D ; RICHMOND, J</creator><creatorcontrib>CALLE, R ; MCCARTHY, M. I ; MANCUSO, J ; MILOS, P ; FRYBURG, D ; HOLMAN, R. R ; BANERJEE, P ; ZEGGINI, E ; CULL, C. A ; THORNE, K. I ; WILTSHIRE, S ; TERRA, S ; MEYER, D ; RICHMOND, J</creatorcontrib><description>Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes. We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors. rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus. We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes.</description><identifier>ISSN: 0012-186X</identifier><identifier>EISSN: 1432-0428</identifier><identifier>DOI: 10.1007/s00125-006-0436-8</identifier><identifier>PMID: 17096118</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Albuminuria - genetics ; Amino Acid Substitution ; Aryldialkylphosphatase - genetics ; Associated diseases and complications ; Biological and medical sciences ; Blood Pressure ; Cardiovascular disease ; Creatinine ; Creatinine - blood ; Creatinine - urine ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - enzymology ; Diabetes Mellitus, Type 2 - genetics ; Diabetes. Impaired glucose tolerance ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - enzymology ; Diabetic Nephropathies - genetics ; Diabetic nephropathy ; Disease Progression ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Ethnic Groups ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Genotype ; Humans ; Kidneys ; Laboratories ; Linkage Disequilibrium ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Oxidative stress ; Plasma ; Polymorphism, Genetic ; Polymorphism, Single Nucleotide ; R&amp;D ; Research &amp; development ; Urinary system involvement in other diseases. Miscellaneous</subject><ispartof>Diabetologia, 2006-12, Vol.49 (12), p.2892-2899</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</citedby><cites>FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18299724$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17096118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CALLE, R</creatorcontrib><creatorcontrib>MCCARTHY, M. I</creatorcontrib><creatorcontrib>MANCUSO, J</creatorcontrib><creatorcontrib>MILOS, P</creatorcontrib><creatorcontrib>FRYBURG, D</creatorcontrib><creatorcontrib>HOLMAN, R. R</creatorcontrib><creatorcontrib>BANERJEE, P</creatorcontrib><creatorcontrib>ZEGGINI, E</creatorcontrib><creatorcontrib>CULL, C. A</creatorcontrib><creatorcontrib>THORNE, K. I</creatorcontrib><creatorcontrib>WILTSHIRE, S</creatorcontrib><creatorcontrib>TERRA, S</creatorcontrib><creatorcontrib>MEYER, D</creatorcontrib><creatorcontrib>RICHMOND, J</creatorcontrib><title>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</title><title>Diabetologia</title><addtitle>Diabetologia</addtitle><description>Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes. We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors. rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus. We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes.</description><subject>Albuminuria - genetics</subject><subject>Amino Acid Substitution</subject><subject>Aryldialkylphosphatase - genetics</subject><subject>Associated diseases and complications</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure</subject><subject>Cardiovascular disease</subject><subject>Creatinine</subject><subject>Creatinine - blood</subject><subject>Creatinine - urine</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - enzymology</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - enzymology</subject><subject>Diabetic Nephropathies - genetics</subject><subject>Diabetic nephropathy</subject><subject>Disease Progression</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Ethnic Groups</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Genotype</subject><subject>Humans</subject><subject>Kidneys</subject><subject>Laboratories</subject><subject>Linkage Disequilibrium</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oxidative stress</subject><subject>Plasma</subject><subject>Polymorphism, Genetic</subject><subject>Polymorphism, Single Nucleotide</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><issn>0012-186X</issn><issn>1432-0428</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpdkd1rFDEUxUOxtGv1D_BFgmCxD1NvMpl89E3a2orFLmjBt5DJB06ZScZkpnT_e2fZhYJPl8v5nQP3HoTeETgnAOJzASC0qQB4BazmlTxAK8JqumxUvkKrrVwRyX8fo9elPAJA3TB-hI6JAMUJkSvk1yab9JyiKR5T_Gl9_4Oe4TH1myHl8U9XhoJNdNj5J9-ncfBxwing7KPpsduUMEc7dSniLuJpM24zXGdaP_mCL_DD9_XVTyz4G3QYTF_82_08QQ9fr39d3lZ39zffLr_cVbZWaqqkAhcaDuCElOCtIybUAogH2xBHhGqFCtDY0FJuFGHApWRgfGBOGQptfYJOd7ljTn9nXyY9dMX6vjfRp7loLkmtGkoW8MN_4GOa83JT0YsqmWCcLRDZQTanUrIPeszdYPJGE9DbAvSuAL0UoLcFaLl43u-D53bw7sWx__gCfNwDpljTh2yi7coLJ6lSgrL6H0u2i0c</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>CALLE, R</creator><creator>MCCARTHY, M. I</creator><creator>MANCUSO, J</creator><creator>MILOS, P</creator><creator>FRYBURG, D</creator><creator>HOLMAN, R. R</creator><creator>BANERJEE, P</creator><creator>ZEGGINI, E</creator><creator>CULL, C. A</creator><creator>THORNE, K. I</creator><creator>WILTSHIRE, S</creator><creator>TERRA, S</creator><creator>MEYER, D</creator><creator>RICHMOND, J</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</title><author>CALLE, R ; MCCARTHY, M. I ; MANCUSO, J ; MILOS, P ; FRYBURG, D ; HOLMAN, R. R ; BANERJEE, P ; ZEGGINI, E ; CULL, C. A ; THORNE, K. I ; WILTSHIRE, S ; TERRA, S ; MEYER, D ; RICHMOND, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Albuminuria - genetics</topic><topic>Amino Acid Substitution</topic><topic>Aryldialkylphosphatase - genetics</topic><topic>Associated diseases and complications</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure</topic><topic>Cardiovascular disease</topic><topic>Creatinine</topic><topic>Creatinine - blood</topic><topic>Creatinine - urine</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - enzymology</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - enzymology</topic><topic>Diabetic Nephropathies - genetics</topic><topic>Diabetic nephropathy</topic><topic>Disease Progression</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Ethnic Groups</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Genotype</topic><topic>Humans</topic><topic>Kidneys</topic><topic>Laboratories</topic><topic>Linkage Disequilibrium</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oxidative stress</topic><topic>Plasma</topic><topic>Polymorphism, Genetic</topic><topic>Polymorphism, Single Nucleotide</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CALLE, R</creatorcontrib><creatorcontrib>MCCARTHY, M. I</creatorcontrib><creatorcontrib>MANCUSO, J</creatorcontrib><creatorcontrib>MILOS, P</creatorcontrib><creatorcontrib>FRYBURG, D</creatorcontrib><creatorcontrib>HOLMAN, R. R</creatorcontrib><creatorcontrib>BANERJEE, P</creatorcontrib><creatorcontrib>ZEGGINI, E</creatorcontrib><creatorcontrib>CULL, C. A</creatorcontrib><creatorcontrib>THORNE, K. I</creatorcontrib><creatorcontrib>WILTSHIRE, S</creatorcontrib><creatorcontrib>TERRA, S</creatorcontrib><creatorcontrib>MEYER, D</creatorcontrib><creatorcontrib>RICHMOND, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CALLE, R</au><au>MCCARTHY, M. I</au><au>MANCUSO, J</au><au>MILOS, P</au><au>FRYBURG, D</au><au>HOLMAN, R. R</au><au>BANERJEE, P</au><au>ZEGGINI, E</au><au>CULL, C. A</au><au>THORNE, K. I</au><au>WILTSHIRE, S</au><au>TERRA, S</au><au>MEYER, D</au><au>RICHMOND, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76</atitle><jtitle>Diabetologia</jtitle><addtitle>Diabetologia</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>49</volume><issue>12</issue><spage>2892</spage><epage>2899</epage><pages>2892-2899</pages><issn>0012-186X</issn><eissn>1432-0428</eissn><abstract>Identification of variants predicting development of renal dysfunction would offer substantial clinical benefits. There is evidence that coding non-synonymous variants in the gene encoding paraoxonase 2 (PON2) are associated with nephropathy in both type 1 and type 2 diabetes. We examined the relationship between variation at the C311S and A148G polymorphisms (together with PON2 intronic variant rs12704795) and indices of renal dysfunction (progression to micro- and macroalbuminuria, plasma creatinine increases) in 3,374 newly diagnosed type 2 diabetic subjects from the UK Prospective Diabetes Study followed prospectively (median 14.0 years), using proportional hazards models, adjusted for sex, ethnicity and other known or putative risk factors. rs12704795 genotypes were associated with differing rates of development of microalbuminuria (relative risk [RR] for CC vs AA homozygotes 0.68 [95% CI 0.54-0.87], p=0.002) but not other measures of worsening renal function. Heterozygotes for C311S were more likely to develop microalbuminuria (RR=1.31 [95% CI 1.11-1.54], p=0.001) but less likely to double creatinine levels during follow-up (RR=0.49 [95% CI 0.27-0.89], p=0.02). There was no corroboration of this latter association for related outcomes and no prior evidence supports heterosis effects at this locus. We conclude that the PON2 variants typed in this study have, at best, a small effect on the risk of renal dysfunction in type 2 diabetes.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>17096118</pmid><doi>10.1007/s00125-006-0436-8</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0012-186X
ispartof Diabetologia, 2006-12, Vol.49 (12), p.2892-2899
issn 0012-186X
1432-0428
language eng
recordid cdi_proquest_miscellaneous_68139521
source Springer Link
subjects Albuminuria - genetics
Amino Acid Substitution
Aryldialkylphosphatase - genetics
Associated diseases and complications
Biological and medical sciences
Blood Pressure
Cardiovascular disease
Creatinine
Creatinine - blood
Creatinine - urine
Diabetes
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - enzymology
Diabetes Mellitus, Type 2 - genetics
Diabetes. Impaired glucose tolerance
Diabetic Nephropathies - blood
Diabetic Nephropathies - enzymology
Diabetic Nephropathies - genetics
Diabetic nephropathy
Disease Progression
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Ethnic Groups
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Genotype
Humans
Kidneys
Laboratories
Linkage Disequilibrium
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Oxidative stress
Plasma
Polymorphism, Genetic
Polymorphism, Single Nucleotide
R&D
Research & development
Urinary system involvement in other diseases. Miscellaneous
title Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes : UKPDS 76
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T06%3A21%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Paraoxonase%202%20(PON2)%20polymorphisms%20and%20development%20of%20renal%20dysfunction%20in%20type%202%20diabetes%20:%20UKPDS%2076&rft.jtitle=Diabetologia&rft.au=CALLE,%20R&rft.date=2006-12-01&rft.volume=49&rft.issue=12&rft.spage=2892&rft.epage=2899&rft.pages=2892-2899&rft.issn=0012-186X&rft.eissn=1432-0428&rft_id=info:doi/10.1007/s00125-006-0436-8&rft_dat=%3Cproquest_cross%3E68139521%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c399t-890df5600d7880ecd1af3701e0c51d179b79f05cfb26a914068840aef4d9a20b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213847464&rft_id=info:pmid/17096118&rfr_iscdi=true